Accurate prediction of lymph-node metastasis in cancers is pivotal for the next targeted clinical interventions that allow favorable prognosis for patients. Different molecular profiles (mRNA and non-coding RNAs) have been widely used to establish classifiers for cancer prediction (e.g., tumor origin, cancerous or non-cancerous state, cancer subtype). However, few studies focus on lymphatic metastasis evaluation using these profiles, and the performance of classifiers based on different profiles has also not been compared. Here, differentially expressed mRNAs, miRNAs, and lncRNAs between lymph-node metastatic and non-metastatic groups were identified as molecular signatures to construct classifiers for lymphatic metastasis prediction in different cancers. With this similar feature selection strategy, support vector machine (SVM) classifiers based on different profiles were systematically compared in their prediction performance. For representative cancers (a total of nine types), these classifiers achieved comparative overall accuracies of 81.00% (67.96-92.19%), 81.97% (70.83-95.24%), and 80.78% (69.61-90.00%) on independent mRNA, miRNA, and lncRNA datasets, with a small set of biomarkers (6, 12, and 4 on average). Therefore, our proposed feature selection strategies are economical and efficient to identify biomarkers that aid in developing competitive classifiers for predicting lymph-node metastasis in cancers. A user-friendly webserver was also deployed to help researchers in metastasis risk determination by submitting their expression profiles of different origins.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905047PMC
http://dx.doi.org/10.3389/fcell.2021.605977DOI Listing

Publication Analysis

Top Keywords

lymph-node metastasis
12
metastasis cancers
12
prediction lymph-node
8
differentially expressed
8
mrna non-coding
8
lymphatic metastasis
8
classifiers based
8
based profiles
8
feature selection
8
metastasis
6

Similar Publications

Cisplatin, a platinum-based chemotherapeutic agent, can be used to treat cervical cancer (CC), but cisplatin resistance is increased during the cisplatin treatment. Long non-coding RNA PGM5-AS1 reportedly participates in CC tumorigenesis; however, its role in CC patients with cisplatin resistance has not been revealed. The present aimed to examine the role of PGM5-AS1 in modulating cisplatin resistance in CC.

View Article and Find Full Text PDF

PrPc is expressed in various tumors and is associated with cancer progression, but previous studies have shown conflicting results regarding its relationship with patient prognosis-potentially due to differences in the antibodies used. This study aimed to clarify the relationship between PrPc expression and primary esophageal squamous cell carcinoma (ESCC) and primary hepatocellular carcinoma (HCC) using a novel anti-PrPc antibody, 4AA-m, noted for its high specificity and sensitivity. We used flow cytometry to detect PrPc expression in ESCC and HCC cell lines.

View Article and Find Full Text PDF

Development and Validation of a Nomogram Based on Multiparametric MRI for Predicting Lymph Node Metastasis in Endometrial Cancer: A Retrospective Cohort Study.

Acad Radiol

December 2024

Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China (Y.T., Y.W., Y.Y., X.Q., Y.H., J.L.); Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning 530021, Guangxi Zhuang Autonomous Region, PR China (J.L.). Electronic address:

Rationale And Objectives: To develop a radiomics nomogram based on clinical and magnetic resonance features to predict lymph node metastasis (LNM) in endometrial cancer (EC).

Materials And Methods: We retrospectively collected 308 patients with endometrial cancer (EC) from two centers. These patients were divided into a training set (n=155), a test set (n=67), and an external validation set (n=86).

View Article and Find Full Text PDF

Should endoscopic submucosal dissection be offered to patients with early colorectal cancer?

Surgery

December 2024

Department of Colorectal Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

Background: Endoscopic submucosal dissection is increasingly used to treat early-stage colorectal cancer. This study evaluated the feasibility of endoscopic submucosal dissection in this setting and the determinants of lymph node metastasis.

Methods: We reviewed patients who underwent colorectal endoscopic submucosal dissection for early-stage colorectal cancer at a tertiary center between 2011 and 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!